United Therapeutics CEO 10b5-1 Sales: 8,000 Shares Sold After Option Exercise
Rhea-AI Filing Summary
Martine A. Rothblatt, Chairperson & CEO of United Therapeutics (UTHR), reported option exercises and share sales under a pre-arranged 10b5-1 plan dated May 2, 2025. On 09/25/2025 and 09/26/2025 she exercised 4,000 options each day at a $120.26 exercise price, resulting in 8,000 underlying shares acquired. Concurrently she sold multiple blocks totaling 8,000 shares across the two days at weighted-average prices in the high $420s to low $430s, with reported weighted averages of $429.0678, $430.2525 and $431.9026 for specific trades. Post-transactions she directly owns 130 shares and indirectly holds large positions through spouse and family trusts totaling several hundred thousand shares.
Positive
- Transactions executed under a pre-arranged 10b5-1 trading plan, signaling pre-planned, non-discretionary activity
- Detailed execution disclosures including weighted-average price ranges and offer to provide trade-level details on request
- Significant indirect ownership retained via spouse and multiple family trusts totaling several hundred thousand shares
Negative
- Reported sale of 8,000 shares following exercises reduces the reporting person’s direct shareholdings to 130 shares
- Large tranche of options subject to planned disposition (up to 294,000 options expiring 03/15/2026) could lead to further sales if executed
Insights
TL;DR Insider exercised 8,000 options and sold 8,000 shares under a 10b5-1 plan, reducing direct holdings while retaining substantial indirect ownership.
The filing documents routine, pre-planned option exercises and share sales by the CEO under a 10b5-1 plan established May 2, 2025. The exercises were at a $120.26 strike with no cash price for the options, producing 8,000 shares acquired and immediate sales executed at weighted-average prices in the ~$428–$432 range. The reporting person still has significant indirect ownership via spouse and multiple family trusts, indicating retained economic exposure despite the sales. For investors, these are non-discretionary, planned transactions rather than ad hoc dispositions.
TL;DR Transactions follow an established 10b5-1 plan and are disclosed with supporting execution price ranges and trust ownership details.
The disclosure includes customary explanatory footnotes describing multiple-trade executions and offers to provide trade-level details on request, meeting good-practice transparency standards. The filing shows substantial indirect holdings in family trusts (over 600,000 shares combined across trusts and spouse), which mitigates concerns about loss of alignment from the reported sales. The use of a 10b5-1 plan and the specified termination triggers (exhaustion of a tranche or 12/31/2025) provide clear parameters for future activity.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Stock Option | 4,000 | $0.00 | -- |
| Exercise | Common Stock | 4,000 | $120.26 | $481K |
| Sale | Common Stock | 1,000 | $426.86 | $427K |
| Sale | Common Stock | 3,000 | $428.677 | $1.29M |
| Exercise | Stock Option | 4,000 | $0.00 | -- |
| Exercise | Common Stock | 4,000 | $120.26 | $481K |
| Sale | Common Stock | 900 | $429.0678 | $386K |
| Sale | Common Stock | 800 | $430.2525 | $344K |
| Sale | Common Stock | 2,300 | $431.9026 | $993K |
| holding | Common Stock | -- | -- | -- |
| holding | Common Stock | -- | -- | -- |
| holding | Common Stock | -- | -- | -- |
| holding | Common Stock | -- | -- | -- |
| holding | Common Stock | -- | -- | -- |
Footnotes (1)
- This exercise and sale of stock options was pursuant to a pre-arranged 10b5-1 trading plan entered into by the reporting person on May 2, 2025. This plan will continue until the earlier of: (a) exhaustion of a tranche of 294,000 stock options that expire March 15, 2026; or (b) December 31, 2025. This transaction was executed in multiple trades at prices ranging from $428.79 to $429.415. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. This transaction was executed in multiple trades at prices ranging from $430.16 to $430.42. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. This transaction was executed in multiple trades at prices ranging from $431.56 to $432.14. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. This transaction was executed in multiple trades at prices ranging from $428.17 to $429.10. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Shares held in family trusts as to which the Reporting Person shares investment power and the Reporting Person and/or immediate family members are beneficiaries. Shares held in family trusts as to which the Reporting Person's spouse is sole trustee and sole beneficiary or co-trustee and settlor with power to revoke. Shares held in family trusts as to which the Reporting Person's spouse shares investment power and the Reporting Person and/or immediate family members are beneficiaries. Shares held in family trusts as to which the Reporting Person is sole trustee and sole beneficiary or co-trustee and settlor with power to revoke.
